leisure time -WSS

leisure time

author：comprehensive 2025-09-30 00:09:02 - browse：396

An illustrated portrait of Eli Lilly's David Ricks and Skovronsky – biotech and pharma coverage from STAT — Eli Lilly CEO David Ricks (left) and Chief Scientific Officer Daniel S. Skovronsky Molly Ferguson for STAT

The partnership that would shape Eli Lilly into one of the biggest success stories in the pharmaceutical industry began with conversations around a relatively minor acquisition.

At the time, David Ricks was running Lilly’s U.S. business and was part of the team charged with evaluating Avid Radiopharmaceuticals, which Lilly would go on to purchase in 2010 for a paltry $300 million — couch change for a multibillion-dollar firm. But what struck Ricks was not the company’s technology, for imaging Alzheimer’s plaques, but Avid’s CEO, Daniel S. Skovronsky.

“Dan’s different,” Ricks told STAT. “I had this sense immediately. Some people get in biotech for the cha-ching.” Skovronsky turned out to be a secret weapon. Within six months, Ricks had been promoted to run Lilly’s biomedicine unit and Skovronsky was working for him.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： BioAge raises $170M for combination therapy with Zepbound

leisure time

focus

WSS

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Medicare Advantage proposed rates disappoint insurers

Biogen shutters digital health group, ends Apple study, in cost cutting move

Inequities make cancer less preventable for women: report

PhRMA lawsuit over Medicare drug price negotiation tossed

Would Medicare drug price negotiations stall in a shutdown?

knowledge

leisure time

entertainment

Apple is now the first public company to be valued at $3 trillion

The Readout: Gilead, Bernie Sanders, and other pharma news

As demand for Covid shots wanes, Moderna seeks its next success

Why did Pfizer dish out millions for a Super Bowl ad?

In age of alternative facts, a scholarly course on calling out crap

For Medicare Advantage, Democrats want stronger protections around AI

Medical leaders decry Supreme Court decision on affirmative action

Mindstrong's demise and the future of mental health care

Wildfire smoke exposes gaps in outdoor worker protections

Senators start work on Medicare physician payment reform

hotspot

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Researchers use wearables data and AI to predict preterm birth risk

Private equity deals in Medicare Advantage declines

Paxlovid should be available without a positive Covid test

Doctors' information doesn't help them choose wisely when sick

STAT Virtual Event: How to Increase Diversity in Clinical Trials

leisure time

focus

focus

focus